Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: Retrospective analysis of 78 cases in a single center over four years

Chemotherapy

Volumn 58, Issue 2, 2012, Pages 134-141

  Pracht, Marc ^a   Le Roux, Guillaume ^c   Sulpice, Laurent ^c   Mesbah, Habiba ^b   Manfredi, Sylvain ^c   Audrain, Odile ^b   Boudjema, Karim ^c   Raoul, Jean Luc ^d   Boucher, Eveline ^a  

^a Eugène Marquis Comprehensive Cancer Center   (France)

^b CS 44229   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d Medical Oncology Unit   (France)

Author keywords

Cholangiocarcinoma; Cirrhosis; Palliative chemotherapy; Primary hepatic tumors; Survival

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVOR; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; INOPERABLE CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIVER; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84860844755     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000337289     Document Type: Article

References (44)

1. Blechacz B, Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-321.
2. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378.
3. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D: Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42: 253-260.
4. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, Makuuchi M: A new staging system for massforming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001; 92: 2374-2383.
5. Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15: 4240-4262.
6. Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buemi A, Tretarre B, Velten M, Dancourt V, Menegoz F, Guizard AV, Mace LJ, Peng J, Bercelli P, Arveux P, Esteve J, Faivre J: Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004; 28: 877-881.
7. Ustundag Y, Bayraktar Y: Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 2008; 14: 6458-6466.
8. Chang KY, Chang JY, Yen Y: Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 2009; 7: 423-427.
9. Farhat MH, Shamseddine AI, Tawil AN, Berjawi G, Sidani C, Shamseddeen W, Barada KA: Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. World J Gastroenterol 2008; 14: 3224-3230.
10. Gores GJ: Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 961-969.
11. Lee CH, Chang CJ, Lin YJ, Yeh CN, Chen MF, Hsieh SY: Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009; 100: 1765-1770.
12. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA: Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626.
13. Wise C, Pilanthananond M, Perry BF, Alpini G, McNeal M, Glaser SS: Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol 2008; 14: 2986-2989.
14. Wu TT, Levy M, Correa AM, Rosen CB, Abraham SC: Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases. Cancer 2009; 115: 4564-4575.
15. Dwary AD, Sharma A, Mohanti BK, Pal S, Garg P, Raina V, Shukla NK, Deo SV, Thulkar S, Sreenivas V: A randomized controlled trial (RCT) comparing best supportive care (BSC), 5-FU plus folinic acid (FUFA) and, gemcitabine plus oxaliplatin (Gem-Ox) in management of unresectable gallbladder cancer (GBC). J Clin Oncol (Meeting Abstracts) 2009; 27: 4521.
16. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
17. André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008; 99: 862-867.
18. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902.
19. Morine Y, Shimada M, Ikegami T, Imura S, Kanemura H, Arakawa Y, Hanaoka J, Kanamoto M, Nii A: Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. Hepatogastroenterology 2009; 56: 307-312.
20. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR: Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92: 1650-1654.
21. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
22. Verslype C, Prenen H, Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 2008; 10: 164-167.
23. Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B: A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005; 41: 398-403.
24. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
25. Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, Han JK, Choi BI: Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 2009; 193:W482-W489.
26. Hollebecque A, Bouche O, Romano O, Scaglia E, Cattan S, Zerbib P, Heurgue A, Lagarde S, Mariette C, Triboulet JP, Pruvot FR, Hebbar M: Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. Chemotherapy 2010; 56: 234-238.
27. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
28. Malka D, Trabach T, Fartoux L, Mendiboure J, de la Fouchardière C, Viret F, Assenat E, Boucher E, Rosmorduc O, Greten T: A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. J Clin Oncol (Meeting Abstracts) 2009; 27: 4520.
29. Malik IA: Gallbladder cancer: current status. Expert Opin Pharmacother 2004; 5: 1271-1277.
30. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458.
31. Aliberti C, Benea G, Tilli M, Fiorentini G: Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 2008; 31: 883-888.
32. Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, Kamel I, Geschwind JF: Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16: 353-361.
33. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, Benson A III, Omary RA, Salem R: Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008; 113: 2119-2128.
34. Saxena A, Bester L, Chua TC, Chu FC, Morris DL: Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17: 484-491.
35. Bakaii-Saab T, Phelps M, Li X, Saji M, Kosuri K, Goff L, Kauh J, O'Neil B, South C, Thomas J, Balsom S, Chattah N, Balint C, Liersemann R, Vasko V, Marsh W, Doyle LA, Ringel M, Villalona Calero M: A multi-institutional study of AZD6244 (ARRY-142886) in patients with advanced biliary cancers. Annual Meeting of the American Association for Cancer Research, Denver, Colo., April 2009.
36. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del GC, Luppi G, Conte P: Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010; 102: 68-72.
37. El-Khoueiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE, Blanke CD: SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol (Meeting Abstracts) 2007; 25: 4630.
38. Gruenberger B, Schueller J, Tamandl D, Kaczirek K, Schernthaner G, Gruenberger T: Kras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabineoxaliplatin (GEMOX): a single center phase II study. J Clin Oncol (Meeting Abstracts) 2009; 27: 4586.
39. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD: Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010; 28: 3491-3497.
40. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24: 3069-3074.
41. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour- Edwards R, Dancey J, Gandara DR: A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783.
42. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV: Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11: 48-54.
43. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T: Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010; 11: 1142-1148.
44. Chung MJ, Kim YJ, Park JY, Bang S, Song SY, Chung JB, Park SW: Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. Chemotherapy 2011; 57: 236-243.